Triglyceride-lowering effect of the aldose reductase inhibitor cemtirestat—another factor that may contribute to attenuation of symptoms of peripheral neuropathy in STZ-diabetic rats
Hyperglycemia is considered a key risk factor for development of diabetic complications including neuropathy. There is strong scientific evidence showing a primary role of aldose reductase, the first enzyme of the polyol pathway, in the cascade of metabolic imbalances responsible for the detrimental effects of hyperglycemia. Aldose reductase is thus considered a significant drug target. We investigated the effects of cemtirestat, a novel aldose reductase inhibitor, in the streptozotocin-induced rat model of uncontrolled type 1 diabetes in a 4-month experiment. Markedly increased sorbitol levels were recorded in the erythrocytes and the sciatic nerve of diabetic animals. Osmotic fragility of red blood cells was increased in diabetic animals. Indices of thermal hypoalgesia were significantly increased in diabetic rats. Tactile allodynia, recorded in diabetic animals in the early stages, turned to mechanical hypoalgesia by the end of the experiment. Treatment of diabetic animals with cemtirestat (i) reduced plasma triglycerides and TBAR levels; (ii) did not affect the values of HbA1c and body weights; (iii) reversed erythrocyte sorbitol accumulation to near control values, while sorbitol in the sciatic nerve was not affected; (iv) ameliorated indices of the erythrocyte osmotic fragility; and (v) attenuated the symptoms of peripheral neuropathy more significantly in the middle of the experiment than at the end of the treatment. Taking into account the lipid metabolism as an interesting molecular target for prevention or treatment of diabetic peripheral neuropathy, the triglyceride-lowering effect of cemtirestat should be considered in future studies. The most feasible mechanisms of triglyceride-lowering action of cemtirestat were suggested.
KeywordsAldose reductase inhibitor Cemtirestat Diabetic peripheral neuropathy STZ-induced diabetic rats Sorbitol accumulation Erythrocyte osmotic fragility Triglycerides
Median corpuscular fragility
Red blood cells
Thiobarbituric acid reactive substances
Peroxisome proliferator-activated receptors
- ZDF rat
Zucker diabetic fatty rat
This work was supported by VEGA 2/0005/2018, Slovak Research and Development Agency, under the contract NO. APVV-15-0455, SAS-Tubitak JRP 2015/7 and TUBITAK Project No: 215S19.
Author contribution statement
MSP, LK, CK, and MS designed and performed research including behavioral and biochemical assays; participated in the interpretation of the results, writing and review of the manuscript. KS, SB and ZE performed behavioral and biochemical assays. All authors read and approved the manuscript.
Compliance with ethical standards
The study was approved by the Ethics Committee of the Institute of Experimental Pharmacology and Toxicology, CEM, SAS, and the State Veterinary and Food Administration of the Slovak Republic, and it was performed in accordance with the Principles of Laboratory Animal Care (NIH publication 83-25, revised 1985) and the Slovak law regulating animal experiments (Decree 289, Part 139, July 9, 2003).
Conflict of interest
The authors declare that they have no conflict of interest
- Ali G, Subhan F, Abbas M, Zeb J, Shahid M, Sewell RD (2015) A streptozotocin-induced diabetic neuropathic pain model for static or dynamic mechanical allodynia and vulvodynia: validation using topical and systemic gabapentin. Naunyn Schmiedeberg’s Arch Pharmacol 388(11):1129–1140. https://doi.org/10.1007/s00210-015-1145-y CrossRefGoogle Scholar
- Calabek B, Callaghan B, Feldman EL (2014) Therapy for diabetic neuropathy: an overview. Chapter 22. In: Zochodne DW, Malik RA (eds) Handbook of clinical neurology. Elsevier, 126:317–333. https://doi.org/10.1016/B978-0-444-53480-4.00022-9 CrossRefGoogle Scholar
- Kyselova Z, Gajdosik A, Gajdosikova A, Ulicna O, Mihalova D, Karasu C, Stefek M (2005) Effect of the pyridoindole antioxidant stobadine on development of experimental diabetic cataract and on lens protein oxidation in rats: comparison with vitamin E and BHT. MolVis 11:56–65Google Scholar
- Lupachyk S, Shevalye H, Maksimchyk Y, Drel VR, Obrosova IG (2011) PARP inhibition alleviates diabetes-induced systemic oxidative stress and neural tissue 4-hydroxynonenal adduct accumulation: correlation with peripheral nerve function. Free Radic Biol Med 50(10):1400–1409. https://doi.org/10.1016/j.freeradbiomed.2011.01.037 CrossRefPubMedPubMedCentralGoogle Scholar
- Obrosova IG, Xu W, Lyzogubov VV, Ilnytska O, Mashtalir N, Vareniuk I, Pavlov IA, Zhang J, Slusher B, Drel VR (2008) PARP inhibition or gene deficiency counteracts intraepidermal nerve fiber loss and neuropathic pain in advanced diabetic neuropathy. Free Radic Biol Med 44(6):972–981CrossRefGoogle Scholar
- Prnova MS, Ballekova J, Majekova M, Stefek M (2015) Antioxidant action of 3-mercapto-5H-1,2,4-triazino[5,6-b]indole-5-acetic acid, an efficient aldose reductase inhibitor, in a 1,1′-diphenyl-2-picrylhydrazyl assay and in the cellular system of isolated erythrocytes exposed to tert-butyl hydroperoxide. Redox Rep 20(6):282–288. https://doi.org/10.1179/1351000215Y0000000019 CrossRefPubMedGoogle Scholar
- Qiu L, Wu X, Chau JF, Szeto IY, Tam WY, Guo Z, Chung SK, Oates PJ, Chung SS, Yang JY (2008) Aldose reductase regulates hepatic peroxisome proliferator-activated receptor alpha phosphorylation and activity to impact lipid homeostasis. J Biol Chem 283(25):17175–17183. https://doi.org/10.1074/jbcM801791200 CrossRefPubMedGoogle Scholar
- Qiu L, Lin J, Xu F, Gao Y, Zhang C, Liu Y, Luo Y, Yang JY (2012) Inhibition of aldose reductase activates hepatic peroxisome proliferator-activated receptor-α and ameliorates hepatosteatosis in diabetic db/db mice. Exp Diabetes Res 2012:789730. https://doi.org/10.1155/2012/789730 CrossRefPubMedGoogle Scholar
- Soltesova Prnova M, Majekova M, Milackova I, Díez-Dacal B, Pérez-Sala D, Ceyhan MS, Banerjee S, Stefek M (2015b) [5-(Benzyloxy)-1H-indol-1-yl] acetic acid, an aldose reductase inhibitor and PPARγ ligand. Acta Biochim Pol 62(3):523–528. https://doi.org/10.18388/abp2014953
- Soltesova Prnova M, Svik K, Bezek S, Kovacikova L, Karasu C, Stefek M (2019) 3-Mercapto-5H-1,2,4-triazino[5,6-b]indole-5-acetic acid (cemtirestat) alleviates symptoms of peripheral diabetic neuropathy in Zucker diabetic fatty (ZDF) rats: a role of aldose reductase. Neurochem Res 44(5):1056–1064. https://doi.org/10.1007/s11064-019-02736-1 CrossRefPubMedGoogle Scholar
- Stefek M, Soltesova Prnova M, Ballekova J, Majekova M (2016) Cemtirestat, a novel aldose reductase inhibitor and antioxidant, in multitarget pharmacology of diabetic complications. Int J Adv Sci Eng Technol 4(3):41–44Google Scholar
- Stefek M, Milackova I, Díez-Dacal B, Pérez-Sala D, Soltesova Prnova M (2017) Use of 5-carboxymethyl-3-mercapto-1,2,4-triazino-[5,6-b] indoles and their pharmaceutical composition. Slovak Patent No 288508Google Scholar
- Travis SF, Morrison AD, Clements RS Jr, Winegrad AI, Oski FA (1971) Metabolic alterations in the human erythrocyte produced by increases in glucose concentration. The role of the polyol pathway. J Clin Invest 50(10):2104–2112. https://doi.org/10.1172/JCI106704 CrossRefPubMedPubMedCentralGoogle Scholar
- Uydu HA, Yıldırmıs S, Orem C et al (2012) The effects of atorvastatin therapy on rheological characteristics of erythrocyte membrane, serum lipid profile and oxidative status in patients with dyslipidemia. J Membr Biol 245:697–705. https://doi.org/10.1007/s00232-012-9441-7 CrossRefPubMedGoogle Scholar
- Vergès B (2011) Lipid disorders in type 1 diabetes, type 1 diabetes - complications, pathogenesis, and alternative treatments, Chih-Pin Liu, IntechOpen. https://doi.org/10.5772/20869. Available from: https://www.intechopen.com/books/type-1-diabetes-complications-pathogenesis-and-alternative-treatments/lipid-disorders-in-type-1-diabetes Google Scholar
- Zhan JY, Ma K, Zheng QC, Yang GH, Zhang HX (2019) Exploring the interactional details between aldose reductase (AKR1B1) and 3-Mercapto-5H-1,2,4-triazino[5,6-b]indole-5-acetic acid through molecular dynamics simulations. J Biomol Struct Dyn 37(7):1724. https://doi.org/10.1080/07391102.2018.1465851 CrossRefGoogle Scholar